Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 586

1.

Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.

Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske SN, Luster M.

Horm Metab Res. 2012 Nov;44(12):904-8. doi: 10.1055/s-0032-1316351. Epub 2012 Jul 12.

PMID:
22791600
2.
3.
4.

Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.

Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, Tanabe H, Fukukura Y, Nakabeppu Y, Koriyama C.

Radiology. 2013 Jun;267(3):891-901. doi: 10.1148/radiol.13121546. Epub 2013 Mar 6.

PMID:
23468571
5.

Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.

Schreinemakers JM, Vriens MR, Munoz-Perez N, Guerrero MA, Suh I, Rinkes IH, Gosnell J, Shen WT, Clark OH, Duh QY.

World J Surg Oncol. 2012 Sep 17;10:192. doi: 10.1186/1477-7819-10-192.

6.

Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.

Mirallié E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodéré F.

Surgery. 2007 Dec;142(6):952-8; discussion 952-8.

PMID:
18063081
7.

Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.

Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S.

Thyroid. 2015 Apr;25(4):437-44. doi: 10.1089/thy.2014.0320. Epub 2015 Mar 16.

PMID:
25633259
8.

Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?

Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.

Thyroid. 2010 Jan;20(1):15-23. doi: 10.1089/thy.2008.0416.

PMID:
20017617
9.

18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.

Dahele M, Ung YC, Ehrlich L, Silverberg J, Balogh J, Wong CS.

J Otolaryngol Head Neck Surg. 2008 Oct;37(5):712-7.

PMID:
19128681
10.

Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.

Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.

Am J Surg. 2000 Jun;179(6):457-61.

PMID:
11004330
11.

Therapeutic impact of (18)F-FDG PET/CT in recurrent differentiated thyroid carcinoma.

Pomerri F, Cervino AR, Al Bunni F, Evangelista L, Muzzio PC.

Radiol Med. 2014 Feb;119(2):97-102. doi: 10.1007/s11547-013-0323-6. Epub 2013 Nov 26.

PMID:
24277507
12.

Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.

Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA.

Head Neck. 2012 May;34(5):626-31. doi: 10.1002/hed.21791. Epub 2011 Aug 17.

PMID:
21850699
13.

Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.

Dennis K, Hay JH, Wilson DC.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e168-72. doi: 10.1016/j.clon.2012.08.002. Epub 2012 Sep 1.

PMID:
22944464
14.

Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.

Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G.

Nucl Med Commun. 2011 Dec;32(12):1162-8. doi: 10.1097/MNM.0b013e32834bbe09.

PMID:
21946617
16.

Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.

Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, Nakamoto Y, Higashi T, Saga T, Konishi J.

Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):491-8. Epub 2003 Dec 10.

PMID:
14666387
17.

Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.

Lee J, Nah KY, Kim RM, Oh YJ, An YS, Yoon JK, An GI, Choi TH, Cheon GJ, Soh EY, Chung WY.

J Korean Med Sci. 2012 Sep;27(9):1019-26. doi: 10.3346/jkms.2012.27.9.1019. Epub 2012 Aug 22.

18.

Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.

Kim MH, O JH, Ko SH, Bae JS, Lim DJ, Kim SH, Baek KH, Lee JM, Kang MI, Cha BY, Lee KW.

Thyroid. 2012 Feb;22(2):157-64. doi: 10.1089/thy.2011.0177. Epub 2012 Jan 6.

PMID:
22224820
19.
20.

Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?

Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.

Ann Nucl Med. 2012 Jan;26(1):77-85. doi: 10.1007/s12149-011-0545-4. Epub 2011 Oct 19.

PMID:
22006540

Supplemental Content

Support Center